Details

Autor(en) / Beteiligte

• Di Palma, Martina
• Gentilini, Elio
• Masucci, Chiara
• Micozzi, Alessandra
• Turriziani, Ombretta
• Mulè, Antonino
• Foà, Robin
• Martelli, Maurizio
• D'Ettorre, Gabriella
• Capria, Saveria
• Chiaretti, Sabina

Titel

Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report

Ist Teil von

• Mediterranean journal of hematology and infectious diseases, 2022-05, Vol.14 (1), p.e2022043

Ort / Verlag

Italy: Università Cattolica del Sacro Cuore

Erscheinungsjahr

2022

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Management of patients with concomitant acute lymphoblastic leukemia (ALL) and COVID-19 infection is challenging. We describe the clinical history of a 40-year-old male with relapsed B-common ALL who developed Sars-CoV2 prior to treatment initiation with inotuzumab. Since the patient was asymptomatic for COVID-19, the first dose of inotuzumab was administered, followed by remdesivir as prophylaxis. However, a worsening in respiratory findings led to a delay in administering the following doses of inotuzumab. Interestingly, even if the patient did not receive the full inotuzumab cycle, he achieved a complete hematologic remission: furthermore, he spontaneously developed anti-sars-COV2 antibodies. COVID-19 treatment also included convalescent plasma, leading to negativization of the viral load. The patient, after COVID-19 recovery, received a second full cycle of inotuzumab, underwent allogeneic transplantation, and is currently in complete hematologic and molecular remission, in good clinical conditions, five months from allograft.